A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (BRAVE I)

The reason for this randomized, double-blind, placebo-controlled, parallel-group, phase 3 study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).

To Learn More Contact
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559
Mon – Fri 9 AM – 5 PM Eastern time (UTC/GMT – 5 hours, EST)Eli Lilly and Company
ClinicalTrials.gov identifier: NCT03616912

Sign up for our Newsletter

Use this tool to search all lupus trials and create a personalized list of studies by the type of lupus you have and where you live.

Sign up